RPRX

Royalty Pharma Plc (RPRX) - Q2 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2026. Royalty Pharma Plc is the largest buyer of biopharmaceutical royalties, operating as a single reportable segment. The company completed the internalization of its management team in May 2025, transitioning from an externally managed structure to an integrated company. As of June 30, 2026, the company held 445.3 million Class A ordinary shares and 129.7 million Class B ordinary shares outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total income increased 16.5% in Q2 2026 and 13.8% YTD compared to 2025, driven by higher interest income from the cystic fibrosis franchise, Tremfya, and new assets like Imdelltra.
• Operating Expenses: Operating expenses increased 46.7% in Q2 2026, primarily due to a $268.2 million provision for changes in expected cash flows (vs. a $203.9 million provision income in Q2 2025). This was driven by forecast declines for Adstiladrin and conservative assumptions regarding the Alyftrek royalty dispute.
• Impairment: The company recorded a $69.4 million non-cash impairment charge in Q1 2026 related to Tazverik following its voluntary withdrawal by Ipsen and Eisai. No impairment was recorded in Q2 2026.
• Share-Based Compensation: G&A expenses included $107.4 million in share-based compensation for Q2 2026, reflecting the post-internalization vesting of Class E Interests and Employee EPAs.
• Debt Structure: Interest expense increased 36.3% in Q2 2026 due to the issuance of $2.0 billion in senior unsecured notes in September 2025 and the assumption of a $380 million term loan during internalization.

Guidance, Outlook, and Risks

• Outlook: Management continues to deploy capital into new royalties, investing $876.7 million in the first six months of 2026. The company maintains a $1.8 billion revolving credit facility and $1.7 billion remaining under its share repurchase program.
• Key Risks:
  • Accounting Volatility: GAAP results are subject to significant volatility due to the effective interest method, where changes in sell-side sales forecasts can trigger immediate non-cash provision expenses or income.
  • Dispute with Vertex: A dispute exists regarding royalty receipts on Alyftrek net sales. The company believes it is contractually entitled to royalties on the deuterated ivacaftor component, but has not received full payments since Q2 2025.
  • Development Risk: Significant exposure to development-stage candidates (e.g., daraxonrasib, TEV-408) where clinical failure or regulatory delays could result in impairment charges.
  • Leverage: The company utilizes significant leverage ($9.2 billion principal debt), subjecting it to interest rate risk and covenant compliance requirements.

Investor Verification Checklist

• Vertex Dispute Status: Verify the current status of the dispute resolution regarding Alyftrek royalties and potential impact on future cash flows.
• Adstiladrin Forecast: Review updated sell-side consensus sales forecasts for Adstiladrin, which drove a significant provision expense in Q2 2026.
• Debt Covenants: Confirm compliance with the Consolidated Leverage Ratio (4.00:1.00) and Portfolio Cash Flow Ratio (5.00:1.00) under the new Revolving Credit Facility.
• Share Repurchase Activity: Monitor the pace of share repurchases under the $3.0 billion program, noting $95.6 million spent in the first half of 2026.
• Internalization Costs: Assess the long-term impact of the 2025 internalization on G&A expenses, specifically the transition from management fees to direct employee compensation and share-based awards.